|1.||Yusuf, Salim: 33 articles (08/2015 - 01/2002)|
|2.||Teo, Koon: 18 articles (07/2015 - 07/2004)|
|3.||Schumacher, Helmut: 18 articles (03/2015 - 01/2002)|
|4.||Gao, Peggy: 16 articles (08/2015 - 10/2009)|
|5.||Sleight, Peter: 15 articles (06/2015 - 01/2002)|
|6.||Unger, Thomas: 15 articles (03/2015 - 05/2003)|
|7.||Mancia, Giuseppe: 13 articles (06/2015 - 01/2008)|
|8.||Teo, Koon K: 12 articles (08/2015 - 04/2008)|
|9.||Schmieder, Roland E: 12 articles (09/2011 - 11/2004)|
|10.||Anderson, Craig: 11 articles (07/2015 - 07/2004)|
|1.||Hypertension (High Blood Pressure)
07/01/2004 - "In Japanese patients with mild-moderate hypertension, telmisartan produced a significant reduction in blood pressure (effective rate: 76.0%) with a good safety profile. "
01/01/2006 - "The consistent antihypertensive efficacy during the entire 24-hour dosage interval and sustained BP-lowering effect in the long term, combined with its favourable tolerability profile, mean that telmisartan is a valuable first-line treatment option for the management of essential hypertension."
07/01/2004 - "Therefore, telmisartan is expected to be effective in the treatment of hypertension, producing sustained 24-h blood pressure control."
03/01/2012 - "An effort was made to formulate a fast dissolving film containing telmisartan which is used in the treatment of hypertension with a view to improve the onset of action, therapeutic efficacy, patient compliance and convenience. "
12/01/2011 - "This paper reviews telmisartan's pharmacological properties in terms of efficacy for hypertension control and, importantly, focuses on its new therapeutic indications and their clinical implications. "
06/01/2012 - "FPI and insulin resistance may be improved with 80 mg of telmisartan."
01/01/2011 - "Treatment with telmisartan not only decreased SBP and DBP levels, but also improved insulin resistance and microalbuminuria by T1. "
01/01/2015 - "This trial will evaluate whether telmisartan can reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy. "
01/01/2015 - "Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy."
08/01/2014 - "A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients."
11/15/2009 - "Is telmisartan effective for stroke prevention?"
09/01/2012 - "This predefined substudy comprised 771 patients (mean age, 65 years) with recent ischemic stroke of noncardioembolic origin who received telmisartan or placebo during a mean follow-up of 27.9 (SD, 7.6) months and had 2 evaluable MRI examinations after index stroke and at study closeout. "
09/01/2012 - "We investigated whether telmisartan prevents WML progression in the imaging substudy of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. "
09/01/2009 - "A careful analysis of the PRoFESS trial, however, reveals study design limitations, the main one being that diastolic BP (<80 mmHg) in the first month post-stroke may have been too low in at least one third of the population with baseline systolic blood pressure less than 130 mmHg, because a high dose of telmisartan was given after a very short post-stroke delay (median 15 days) without discontinuation of the baseline antihypertensive treatment."
05/01/2009 - "Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?"
|4.||Cardiovascular Diseases (Cardiovascular Disease)
06/01/2014 - "In the Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease, all patients were at high cardiovascular risk, and a substantial proportion were hypertensive. "
06/01/2014 - "Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis."
09/01/2011 - "Participants were 3,488 adults at high risk for cardiovascular disease but free from diabetes (mean age 67 years; 61% male) in the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study. "
01/01/2011 - "Similar findings were observed in the Telmisartan Randomized AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial conducted in ACEI-intolerant patients. "
01/01/2010 - "We therefore analyzed data from this study and a parallel study TRANSCEND (Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease). "
01/01/2011 - "The present study was designed to evaluate the dose-response relationship of the anti-inflammatory activity of telmisartan in rat models of chronic inflammation. "
02/05/2015 - "Telmisartan treatment significantly prevented MAPK mediated inflammation and apoptosis. "
01/01/2015 - "Telmisartan could reduce inflammation. "
08/01/2013 - "Renoprotective mechanisms of telmisartan on renal injury and inflammation in SHRSP.Z-Leprfa/IzmDmcr rats."
07/04/2013 - "Results clearly indicate that telmisartan significantly reduced the both oxidative and nitrosative stress, inflammation and cell death in diabetic testes. "
|4.||Angiotensin Receptors (Angiotensin II Receptor)
|3.||Renal Dialysis (Hemodialysis)